RS49513B - Nesolvatiran kristalan 6-hidroksi-2-(4-hidroksifenil)-3-[4-(2-piperidinoetoksi)benzoil]benzo[b]tiofen hidrohlorid - Google Patents

Nesolvatiran kristalan 6-hidroksi-2-(4-hidroksifenil)-3-[4-(2-piperidinoetoksi)benzoil]benzo[b]tiofen hidrohlorid

Info

Publication number
RS49513B
RS49513B YU61495A YU61495A RS49513B RS 49513 B RS49513 B RS 49513B YU 61495 A YU61495 A YU 61495A YU 61495 A YU61495 A YU 61495A RS 49513 B RS49513 B RS 49513B
Authority
RS
Serbia
Prior art keywords
benzo
hydroxyphenyl
benzoyl
hydroxy
unsolvatised
Prior art date
Application number
YU61495A
Other languages
English (en)
Inventor
Smith Elizabeth Labell
Douglas Wayne Luke
McNeill John McGill
Scot Randal Miller
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS49513(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/308,325 external-priority patent/US5629425A/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of YU61495A publication Critical patent/YU61495A/sh
Publication of RS49513B publication Critical patent/RS49513B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Nesolvatiran kristalan 6-hidroksi-2-(4-hidroksifenil)-3-[4-(2-piperidinoetoksi)benzoil]benzo[b] tiofen hidrohlorid, naznačen time, što pokazujeu osnovi sledeći rentgenogram sa difrakcijom dobijen radijacijom bakra: Konstanta d-linije ; I/I0 m10-10 ; (x100) 13.3864 ; 71.31 9.3598 ; 33.16 8.4625 ; 2.08 7.3888 ; 7.57 6.9907 ; 5.80 6.6346 ; 51.04 6.1717 ; 29.57 5.9975 ; 5.67 5.9135 ; 9.87 5.6467 ; 38.47 5.4773 ; 10.54 5.2994 ; 4.74 4.8680 ; 4.03 4.7910 ; 5.98 4.6614 ; 57.50 4.5052 ; 5.75 5.3701 ; 9.03 4.2516 ; 69.99 4.2059 ; 57.64 4.1740 ; 65.07 4.0819 ; 12.44 3.9673 ; 22.53 3.9318 ; 100.00 3.8775 ; 9.07 3.7096 ; 33.38 3.6561 ; 21.65 3.5576 ; 3.36 3.5037 ; 7.97 3.4522 ; 18.02 3.4138 ; 4.65 3.2738 ; 10.23 3.1857 ; 8.90 3.1333 ; 6.24 3.0831 ; 9.43 3.0025 ; 12.13 2.9437 ; 4.96 2.8642 ; 7.70 2.7904 ; 11.95 2.7246 ; 3.05 2.6652 ; 3.32 2.5882 ; 7.30 i što je u osnovi oslobodjeno mirisa. Prijava sadrži još 1 nezavisan i 2 zavisna patentna zahteva.
YU61495A 1994-09-19 1995-09-19 Nesolvatiran kristalan 6-hidroksi-2-(4-hidroksifenil)-3-[4-(2-piperidinoetoksi)benzoil]benzo[b]tiofen hidrohlorid RS49513B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/308,325 US5629425A (en) 1994-09-19 1994-09-19 Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US42791495A 1995-04-26 1995-04-26

Publications (2)

Publication Number Publication Date
YU61495A YU61495A (sh) 1998-05-15
RS49513B true RS49513B (sr) 2006-10-27

Family

ID=26976194

Family Applications (2)

Application Number Title Priority Date Filing Date
YUP-613/95A RS49578B (sr) 1994-09-19 1995-09-19 Postupak za dobijanje 6-hidroksi-2-(4- hidroksifenil)-3-[4-(2-piperidinoetoksi) benzoil]benzo[b]tiofen hidrohlorida
YU61495A RS49513B (sr) 1994-09-19 1995-09-19 Nesolvatiran kristalan 6-hidroksi-2-(4-hidroksifenil)-3-[4-(2-piperidinoetoksi)benzoil]benzo[b]tiofen hidrohlorid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
YUP-613/95A RS49578B (sr) 1994-09-19 1995-09-19 Postupak za dobijanje 6-hidroksi-2-(4- hidroksifenil)-3-[4-(2-piperidinoetoksi) benzoil]benzo[b]tiofen hidrohlorida

Country Status (51)

Country Link
US (4) US6472531B1 (sr)
JP (2) JPH08193081A (sr)
KR (2) KR100381346B1 (sr)
CN (2) CN1075069C (sr)
AP (1) AP754A (sr)
AT (2) AT407988B (sr)
AU (3) AU691955B2 (sr)
BE (2) BE1009625A3 (sr)
BG (1) BG62793B1 (sr)
BR (2) BR9504059A (sr)
CA (2) CA2158399C (sr)
CH (3) CH691594A5 (sr)
CO (2) CO4410190A1 (sr)
CZ (2) CZ292007B6 (sr)
DE (3) DE19534745B4 (sr)
DK (4) DK175897B1 (sr)
EE (1) EE03386B1 (sr)
EG (1) EG23763A (sr)
ES (2) ES2109882B1 (sr)
FI (2) FI121424B (sr)
FR (2) FR2732020B1 (sr)
GB (2) GB2293602B (sr)
GE (1) GEP19991821B (sr)
GR (2) GR1002697B (sr)
HK (1) HK1019009A1 (sr)
HR (2) HRP950482B1 (sr)
HU (2) HU225417B1 (sr)
IE (2) IE950722A1 (sr)
IL (3) IL125283A (sr)
IS (1) IS1788B (sr)
IT (2) IT1277601B1 (sr)
LU (2) LU88661A1 (sr)
LV (2) LV11178B (sr)
MY (1) MY116371A (sr)
NL (2) NL1001194C2 (sr)
NO (2) NO308107B1 (sr)
NZ (2) NZ280028A (sr)
OA (1) OA10406A (sr)
PE (2) PE14796A1 (sr)
PL (2) PL182450B1 (sr)
PT (2) PT101771B (sr)
RO (2) RO115260B1 (sr)
RS (2) RS49578B (sr)
SE (2) SE509265C2 (sr)
SI (2) SI9500293A (sr)
SK (1) SK283502B6 (sr)
TR (1) TR199501136A2 (sr)
TW (1) TW412534B (sr)
UA (2) UA42716C2 (sr)
UY (1) UY24040A1 (sr)
WO (1) WO1996009045A1 (sr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
EP0910369B1 (en) * 1996-03-26 2010-04-21 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
RU2203060C2 (ru) 1996-10-30 2003-04-27 Эли Лилли Энд Компани Способ профилактики рака молочной железы
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
CA2372720C (en) 1999-05-04 2007-09-11 John Antony Kanis Androgen glycosides and androgenic activity thereof
US6921827B2 (en) * 2000-11-27 2005-07-26 Eli Lilly And Company Process for preparing 3-aryl-benzo{b} thiophenes
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2499819A1 (en) * 2002-09-30 2004-04-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US8877933B2 (en) 2004-09-29 2014-11-04 Bayer Intellectual Property Gmbh Thermodynamically stable form of a tosylate salt
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US8344149B2 (en) * 2006-10-17 2013-01-01 Cipla Limited Crystalline form of benzothiophene compound and process for preparation thereof
US20080103295A1 (en) * 2006-10-25 2008-05-01 David Losan Ho Process for the preparation of sucrose-6-ester by esterification in the presence of solid superacid catalyst
US8258291B2 (en) * 2006-10-25 2012-09-04 Mamtek International Limited Process for the preparation of sucralose by the chlorination of sugar with triphosgene (BTC)
DE102007032451B4 (de) 2007-07-12 2010-09-30 Icfs Gmbh Verfahren zur Herstellung von aromatischen Ketonen
WO2009015004A1 (en) * 2007-07-20 2009-01-29 King Pharmaceuticals Research And Development, Inc. Crystals of (2-amino-4,5,6,7-tetrahydrobenzo[b]thien-3-yl)(4-chlorophenyl)methanone
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
EP2242483B1 (en) * 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
WO2009150669A1 (en) * 2008-06-09 2009-12-17 Erregierre S.P.A. Process for controlling the growth of a raloxifene hydrochloride crystal
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
ES2437916T3 (es) 2009-07-02 2014-01-15 Synthon B.V. Composición de raloxifeno
EP2314581B1 (en) 2009-10-23 2012-07-25 Hexal AG A process for preparing benzo[b]thiophene derivatives
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
IN2013MU00665A (sr) 2013-03-05 2015-07-03 Cipla Ltd
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104496963A (zh) * 2014-12-02 2015-04-08 千辉药业（安徽）有限责任公司 一种盐酸雷洛昔芬的制备方法
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869485A (en) * 1969-09-25 1975-03-04 Allied Chem Preparation of acid chlorides with phosgene in the presence of a catalyst
GB1456323A (en) * 1974-06-06 1976-11-24 Labaz Benzothiophenes process for preparing them and pharmaceutical compositions containing the same
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
IL65378A (en) * 1981-04-03 1986-02-28 Lilly Co Eli Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes
IL65379A0 (en) 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
AU555658B2 (en) * 1981-04-03 1986-10-02 Eli Lilly And Company Benzothiophene compounds
ZA822247B (en) 1981-04-03 1983-11-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4358593A (en) * 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
DE4117512A1 (de) * 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5169860A (en) 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
DE69405491T2 (de) * 1993-06-24 1998-02-19 Lilly Co Eli Antiöstrogene 2-Phenyl-3-Aroylbenzothiophene als hypoglykämische Mittel
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5523416A (en) 1994-07-22 1996-06-04 Eli Lilly And Company Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO

Also Published As

Publication number Publication date
NO953657L (no) 1996-03-20
NO953657D0 (no) 1995-09-15
ES2129293A1 (es) 1999-06-01
FI954402A (fi) 1996-03-20
US5731327A (en) 1998-03-24
BG101242A (en) 1998-03-31
GB2293602B (en) 1998-05-06
GR1002697B (el) 1997-05-22
AU3173095A (en) 1996-04-04
ITMI951935A0 (it) 1995-09-15
CO4410191A1 (es) 1997-01-09
UA44240C2 (uk) 2002-02-15
FR2724655B1 (fr) 1997-11-14
LV11177B (en) 1996-08-20
DK102895A (da) 1996-03-20
FI121424B (fi) 2010-11-15
IL115314A0 (en) 1996-05-14
PT101770A (pt) 1996-04-30
NL1001194A1 (nl) 1996-03-19
PT101771A (pt) 1996-04-30
GR1002709B (el) 1997-06-04
HUT74178A (en) 1996-11-28
HRP950482B1 (en) 2007-04-30
HRP950482A2 (en) 1998-02-28
US6472531B1 (en) 2002-10-29
JPH08193081A (ja) 1996-07-30
US20020173645A1 (en) 2002-11-21
LU88661A1 (fr) 1996-07-15
ES2109882B1 (es) 1998-08-16
CA2158400C (en) 2006-10-24
UA42716C2 (uk) 2001-11-15
CO4410190A1 (es) 1997-01-09
ES2109882A1 (es) 1998-01-16
DE19534745A1 (de) 1996-04-04
FI954403A (fi) 1996-03-20
CH691125A5 (de) 2001-04-30
SK283502B6 (sk) 2003-08-05
YU61495A (sh) 1998-05-15
FR2732020A1 (fr) 1996-09-27
SI9500293A (en) 1996-06-30
DK2797A (da) 1997-01-09
NZ280027A (en) 1997-05-26
US6399778B1 (en) 2002-06-04
CZ292007B6 (cs) 2003-07-16
SE9503214D0 (sv) 1995-09-15
PL310518A1 (en) 1996-04-01
CZ290343B6 (cs) 2002-07-17
EE9700055A (et) 1997-08-15
FR2724655A1 (fr) 1996-03-22
CN1068324C (zh) 2001-07-11
PL187686B1 (pl) 2004-09-30
IE950721A1 (en) 1996-03-20
KR100367376B1 (ko) 2003-03-06
CA2158400A1 (en) 1996-03-20
PT101771B (pt) 1997-04-30
DK175903B1 (da) 2005-06-06
HUT75033A (en) 1997-03-28
CH691478A5 (de) 2001-07-31
KR960010634A (ko) 1996-04-20
WO1996009045A1 (en) 1996-03-28
CZ240295A3 (en) 1996-04-17
IL115315A (en) 1999-09-22
FI112226B (fi) 2003-11-14
NO313996B1 (no) 2003-01-13
CN1127253A (zh) 1996-07-24
HRP950483A2 (en) 1997-10-31
HU227683B1 (en) 2011-11-28
JP2860071B2 (ja) 1999-02-24
KR100381346B1 (ko) 2004-04-13
DK102795A (da) 1996-03-20
YU61395A (sh) 1998-09-18
FR2732020B1 (fr) 1997-11-14
HRP950483B1 (en) 2003-02-28
NL1001194C2 (nl) 1997-04-04
AU691955B2 (en) 1998-05-28
IE80883B1 (en) 1999-05-19
CZ240395A3 (en) 1996-04-17
TR199501136A2 (tr) 1996-06-21
DK175886B1 (da) 2005-05-23
IS1788B (is) 2001-11-28
DE19534745B4 (de) 2004-06-09
GEP19991821B (en) 1999-11-05
AU3718695A (en) 1996-04-09
CA2158399C (en) 2001-03-20
IT1277601B1 (it) 1997-11-11
SE509265C2 (sv) 1998-12-21
IE950722A1 (en) 1996-03-20
ITMI951936A1 (it) 1997-03-15
KR960010637A (ko) 1996-04-20
HU9502723D0 (en) 1995-11-28
LV11178B (en) 1996-08-20
CH691594A5 (de) 2001-08-31
SE9503213D0 (sv) 1995-09-15
CN1132205A (zh) 1996-10-02
GB9519032D0 (en) 1995-11-15
GB2293382A (en) 1996-03-27
GB2293602A (en) 1996-04-03
IL115314A (en) 2000-02-29
TW412534B (en) 2000-11-21
LV11177A (lv) 1996-04-20
PL182450B1 (pl) 2002-01-31
BR9504059A (pt) 1996-09-24
MY116371A (en) 2004-01-31
DK175887B1 (da) 2005-05-23
AT407988B (de) 2001-07-25
SI9500292A (en) 1996-06-30
OA10406A (en) 2001-12-05
FI954403A0 (fi) 1995-09-18
RS49578B (sr) 2007-04-10
JPH08176147A (ja) 1996-07-09
HK1019009A1 (en) 2000-01-14
IL125283A (en) 2001-06-14
IL115315A0 (en) 1995-12-31
BE1009626A3 (fr) 1997-06-03
EG23763A (en) 2007-08-08
HU9502721D0 (en) 1995-11-28
IS4446A (is) 1997-03-18
FI954402A0 (fi) 1995-09-18
AP754A (en) 1999-07-22
NO953658L (no) 1996-03-20
PL310517A1 (en) 1996-04-01
ATA154295A (de) 2000-12-15
HU225417B1 (en) 2006-11-28
CN1075069C (zh) 2001-11-21
ITMI951936A0 (it) 1995-09-15
EE03386B1 (et) 2001-04-16
AP9700938A0 (en) 1997-04-30
PE14796A1 (es) 1996-05-19
BE1009625A3 (fr) 1997-06-03
SE520721C2 (sv) 2003-08-12
BR9504060A (pt) 1996-09-24
ITMI951935A1 (it) 1997-03-15
UY24040A1 (es) 1996-03-07
AU3173195A (en) 1996-04-04
AU692907B2 (en) 1998-06-18
NZ280028A (en) 1997-05-26
LU88660A1 (fr) 1996-07-15
DK175897B1 (da) 2005-05-30
IT1277602B1 (it) 1997-11-11
GB2293382B (en) 1998-08-19
SE9503214L (sv) 1996-03-20
GB9519028D0 (en) 1995-11-15
DE19534744A1 (de) 1996-03-21
RO115259B1 (ro) 1999-12-30
ES2129293B1 (es) 2000-01-16
LV11178A (lv) 1996-04-20
CA2158399A1 (en) 1996-03-20
NO953658D0 (no) 1995-09-15
DE19549755B4 (de) 2005-05-04
NL1001196A1 (nl) 1996-03-19
NO308107B1 (no) 2000-07-24
RO115260B1 (ro) 1999-12-30
BG62793B1 (bg) 2000-08-31
PE32796A1 (es) 1996-08-07
NL1001196C2 (nl) 1997-04-04
SE9503213L (sv) 1996-03-20
AT502957A1 (de) 2007-06-15
PT101770B (pt) 1997-04-30
SK23397A3 (en) 1997-08-06
DK2897A (da) 1997-01-09

Similar Documents

Publication Publication Date Title
RS49513B (sr) Nesolvatiran kristalan 6-hidroksi-2-(4-hidroksifenil)-3-[4-(2-piperidinoetoksi)benzoil]benzo[b]tiofen hidrohlorid
DK199900904A (da) Nye O-acyloxim-fotoinitiatorer
DE69718026D1 (de) Fluorierte 1,4-disubstituierte piperidin-derivate
ID25654A (id) Implan-implan biji radioaktif
NO985293D0 (no) Nye 2,3-disubstituerte-4(3H)-kinazolinoner
CY1108348T1 (el) Υποκατεστημενα 2-(2,6-διοξοπιπεριδιν-3-υλ)-φθαλιμιδια και μεθοδος μειωσης των tnf αλφα επιπεδων
IS5358A (is) Útskiptar 1,2,3,4-tetrahýdrónaftalen afleiður
ATE277906T1 (de) 4-carboxamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp inhibitoren
TR199900781T2 (xx) H�cre yap��ma inhibit�rleri
NO983356D0 (no) Nye 19-nor-pregnenderivater
DK0512349T3 (da) Benzothiophen-2-carboxamid-S,S-dioxider
NO980814L (no) Nye 2,3-diokso-1,2,3,4-tetrahydro-quinoksalinylderivater
ID26353A (id) Bisindolimaleimida tersubstitusi untuk inhibisi proliferasi sel
DK1216284T3 (da) R 22-erstatningskölemiddel
NO983802L (no) Benzothiofener, formuleringer inneholdende samme og fremgangsmåter
DZ2292A1 (fr) Méthode concernant l'immortalité des cellules.
HRP20000503B1 (en) A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-/2-(PIPERIDIN-1-YL)ETHOXY/PHENOXY)-2-(4-METHOXYPHENYL)BENZO/b/THIOPHENE HYDROCHLORIDE
DZ2556A1 (fr) Compositions nouvelles d'inhibiteur sélectif de réabsorption de sérotonine et d'un beta-bloquant.
ID17424A (id) Penghambat matriks metaloproteasa oleh senyawa-senyawa fenetil tersubstitusi
ITTO920689A1 (it) Generatore di forme d'onda.
NO981216D0 (no) Nye heterosykliske forbindelser
ITRM930232A0 (it) Derivato di benzo b tiofen-5-ile e procedimento per la sua produzione.
NO993013L (no) Nye heterosykliske substituerte pyrrolidinamidderivater
DK1135128T3 (da) Nye behandlingsfremgangsmåder
DZ3193A1 (fr) Méthode d'encryptage multi-modules.